During February 2021, the number of shares and votes in Alligator Bioscience AB (“Alligator”) has increased as a result of the completion of the rights issue of shares resolved upon by the Board of Directors of Alligator on December 15, 2020. Per February 26, 2021, the number of registered shares and votes in Alligator amounts to 85,666,338.
For more information, please contact:
Per Norlén, CEO
Phone: +46 46 540 82 00
E-mail: per.norlen@alligatorbioscience.com
Marie Svensson, CFO
Phone: +46 46 540 82 03
E-mail: marie.svensson@alligatorbioscience.com
This information is such information as Alligator Bioscience AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 11.00 CET on February 26, 2021.
About Alligator Bioscience AB
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets ATOR-1017 and mitazalimab. Furthermore, there are two partnered assets: ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development by Shanghai Henlius Biotech Inc. In addition, the company has developed a novel concept for more patient-specific immunotherapy: Neo-X-Prime. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.